Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company ...
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on ...
Bengaluru Metro Phase 3’s Orange Line Project to axe 1,092 trees has sparked outrage among residents and environmental ...
Town leaders are looking to begin the second phase of development of McCord Square soon as the new town center comes to life.
Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma announced that its drug imlifidase successfully met the primary endpoint ...
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
In the randomized, double-blind, pediatric and adolescent, placebo-controlled study, CTx-1301 delivered rapid onset of effect and sustained efficacy through the evening hours. Safety and tolerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results